Cardiff Oncology

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cardiff Oncology reports strong Q3 performance and strategic growth plans

Cardiff Oncology's Q3 2023 performance reflects strong progress with positive data from their lead program and promising efficacy of onvansertib, supported by a solid financial position.
While the company faces challenges in maintaining clinical trial progress and managing expenses, strategic strengths like the expanded partnership with Pfizer and focus on shareholder value creation position them well for future growth.
Opportunities lie in advancing their lead program, exploring new therapeutic indications, and leveraging collaborations to drive market penetration and enhance competitiveness in the oncology space.

Cardiff Oncology reports strong Q4 performance and strategic advancements

Cardiff Oncology's Q4 2023 earnings call highlighted a strategic shift in their mCRC program, positive clinical data from the ONSEMBLE trial, and a strong financial position. While facing challenges in addressing various analyst inquiries, the company is well-positioned to capitalize on opportunities in expanding their treatment portfolio and leveraging trial data for market differentiation.

Cardiff Oncology reports positive data and strong financial position

Cardiff Oncology's Q1 2024 earnings call highlighted positive data on onvansertib, ongoing trials, and a healthy financial position. Challenges include trial enrollment pace and follow-up data requirements. However, the company has opportunities for growth through successful trials and leveraging preclinical data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ubiquiti Inc

Vodafone Group

Advantest Corp

Deere & Company

Esperion Therapeutics

Fluence Energy

StealthGas

Huntington Ingalls Industries

Himax Tech

Payoneer Global

Ready Capital Corp

Teradyne

TORM

The 'Undercovered' Dozen series highlights lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Ubiquiti Inc. shows promise with operational improvements, Ready Capital Corporation faces liquidity risks, and TORM plc is crucial despite energy sector volatility. Esperion Therapeutics' breakout and Cardiff Oncology's promising trial data present compelling buy opportunities, while Advantest Corporation's high valuation suggests caution.

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk.

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The company plans to discuss with the FDA to potentially make the CRDF-004 trial a registrational trial, aiming for accelerated approval based on ORR. Cardiff's recent $40 million oversubscribed direct offering strengthens its financial position, ensuring over two years of operational funding.

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (“Cardiff Oncology” or the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the pricing of an underwritten offering of 15,384,619 shares of its common stock at an offering price of $2.60 per share, before deducting underwriting discounts and commissions. All of the shares of common stock are being offered by the Company. The financing included participation from new mutual fund and healthcare dedicated investors, along with support from existing investors.

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm -

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.

Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC -

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer.

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC. Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions.

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.

Cardiff Oncology to Present at Upcoming Investor Conferences in May

BTCS

Regulus Therapeutics

Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains.

The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028

Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q1 2024 Results Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Mark Frahm - TD Cowen Joseph Catanzaro - Piper Sandler Andy Hsieh - William Blair Operator Welcome to the Cardiff Oncology First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates

- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program -

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Blink Charging

Hive Blockchain Technologies Ltd

Novavax

Riot Blockchain

Vaxart

The 2024 presidential election is shaping up to be just as exciting and contentious the 2020 contest. That's because it looks to be a rematch between President Biden and former President Trump.

Election Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?

RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC – Therapeutic areas outside of RAS-mutated mCRC – In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status – – In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors – SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, 2024, in San Diego, California. In combination, the abstracts underscore the significant potential of the company's lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why

AdTheorent Holding Company Inc

OrganiGram Holdings Inc.

You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

News for Cardiff Oncology Stock (CRDF)